Targeting interference of CTLA-4 co-inhibition to tumour specific T cells to enhance activity and reduce toxicity
Blockade of Cytotoxic T lymphocyte antigen-4 (CTLA-4) can enhance anti-tumour responses in preclinical models. A monoclonal antibody targeting human CTLA-4 (αCTLA4 mAb), is FDA approved for clinical use against metastatic melanoma. Paradigms suggest that αCTLA4 mAb blocks CTLA-4 dually on CTLA-4hi T...
| Main Author: | |
|---|---|
| Other Authors: | |
| Published: |
University College London (University of London)
2016
|
| Subjects: | |
| Online Access: | https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.746166 |